Summary of Evogene's Q4 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: Total revenue for 2025 was approximately $3.9 million, down from $5.6 million in 2024. Q4 2025 revenue was approximately $0.3 million, a decline from $1.5 million in Q4 2024.

Operating Expenses: Operating expenses decreased significantly to about $13.8 million for the year, compared to $22 million in 2024. Q4 operating expenses were approximately $3.2 million, down from $4.3 million in Q4 2024.

Net Loss: The net loss for 2025 was approximately $7.8 million, a notable improvement from $18.1 million in 2024. However, Q4 2025 net loss increased to approximately $5.4 million from $5,000 in Q4 2024.

Cash Position: As of December 31, 2025, Evogene had approximately $13 million in cash. Cash usage in Q4 2025 was about $3 million.

2Strategic Updates and Business Highlights

Focus on ChemPass AI: Evogene has streamlined its operations to concentrate on its ChemPass AI platform, which is aimed at generating novel small molecules for drug development and ag chemicals.

Collaborations: The company is advancing multiple partnered drug discovery programs and has ongoing collaborations with major firms like Google Cloud, Bayer, and Corteva.

Divestitures: Evogene divested Lavie Bio's majority operations and scaled down Biomica, reallocating resources to enhance its core technology and market focus.

3Forward Guidance and Outlook

Evogene aims to become the partner of choice for small molecule discovery and optimization in both pharma and agriculture sectors.

The company expects to maintain reduced operating expenses and has sufficient cash for at least 1.5 years without additional financing.

Future catalysts include potential collaborations with larger biotech and chemical companies, which could provide cash inflows.

4Bad News, Challenges, or Points of Concern

Revenue Decline: The significant drop in revenue from AgPlenus and Casterra, particularly due to reduced seed sales and an inventory impairment of $2.2 million, raises concerns about market demand.

Increased Operating Loss: Despite reduced expenses, the Q4 operating loss increased, indicating challenges in revenue generation.

Market Conditions: The agricultural and biotech sectors have faced headwinds, affecting collaboration appetites and overall market performance.

5Notable Q&A Insights

BMC128 License Agreement: The agreement with Lishan Pharmaceuticals includes milestone payments and revenue sharing, which could be significant for Evogene.

Cash from Lavie Bio and Biomica: Expected distributions from these subsidiaries are anticipated to support operations through mid-2026.

Future Catalysts: Management highlighted three key areas for potential growth: technology collaborations, partnerships with biotech companies, and collaborations with chemical firms, emphasizing a strategic pivot towards innovation and partnerships. Overall, Evogene is navigating a transformative phase with a clear focus on its AI capabilities while managing financial challenges and market dynamics.